Long-term Study of FK949E in Elderly Bipolar Disorder Patients
Status:
Completed
Trial end date:
2016-06-29
Target enrollment:
Participant gender:
Summary
FK949E was administered to elderly bipolar disorder patients with major depressive episode
for 52 weeks. Its safety, efficacy, and plasma concentration change were evaluated in an
open-label manner.